Computed Tomography Screening for Lung Cancer A High-Value Proposition?

被引:4
|
作者
Roth, Joshua A. [1 ,2 ,3 ]
Ramsey, Scott D. [1 ,2 ,3 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, Hutchinson Inst Canc Outcomes Res, 1100 Fairview Ave N,M2-B230, Seattle, WA 98109 USA
[3] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA
来源
基金
美国医疗保健研究与质量局;
关键词
COST-EFFECTIVENESS; TRIAL;
D O I
10.1001/jama.2015.17877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The US National Lung Screening Trial supports screening for lung cancer among smokers using low-dose computed tomographic (LDCT) scans. The cost-effectiveness of screening in a publicly funded health care system remains a concern. OBJECTIVE To assess the cost-effectiveness of LDCT scan screening for lung cancer within the Canadian health care system. DESIGN, SETTING, AND PARTICIPANTS The Cancer Risk Management Model (CRMM) simulated individual lives within the Canadian population from 2014 to 2034, incorporating cancer risk, disease management, outcome, and cost data. Smokers and former smokers eligible for lung cancer screening (30 pack-year smoking history, ages 55-74 years, for the reference scenario) were modeled, and performance parameters were calibrated to the National Lung Screening Trial (NLST). The reference screening scenario assumes annual scans to age 75 years, 60% participation by 10 years, 70% adherence to screening, and unchanged smoking rates. The CRMM outputs are aggregated, and costs (2008 Canadian dollars) and life-years are discounted 3% annually. MAIN OUTCOMES AND MEASURES The incremental cost-effectiveness ratio. RESULTS Compared with no screening, the reference scenario saved 51 000 quality-adjusted life-years (QALY) and had an incremental cost-effectiveness ratio of CaD $52 000/QALY. If smoking history is modeled for 20 or 40 pack-years, incremental cost-effectiveness ratios of CaD $62 000 and CaD $43 000/QALY, respectively, were generated. Changes in participation rates altered life-years saved but not the incremental cost-effectiveness ratio, while the incremental cost-effectiveness ratio is sensitive to changes in adherence. An adjunct smoking cessation program improving the quit rate by 22.5% improves the incremental cost-effectiveness ratio to CaD $24 000/QALY. CONCLUSIONS AND RELEVANCE Lung cancer screening with LDCT appears cost-effective in the publicly funded Canadian health care system. An adjunct smoking cessation program has the potential to improve outcomes.
引用
收藏
页码:77 / +
页数:2
相关论文
共 50 条
  • [1] Computed tomography screening for lung cancer
    Berg, Christine D.
    Aberle, Denise R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (05): : 513 - 514
  • [2] Computed tomography screening for lung cancer
    Sudarshan, Monisha
    Murthy, Sudish
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2020, 68 (07) : 660 - 664
  • [3] Computed tomography screening for lung cancer
    Becker, N.
    RADIOLOGE, 2013, 53 (09): : 757 - +
  • [4] Computed tomography screening for lung cancer
    Monisha Sudarshan
    Sudish Murthy
    General Thoracic and Cardiovascular Surgery, 2020, 68 : 660 - 664
  • [5] Computed tomography screening for lung cancer
    Bach, Peter
    CLINICAL CANCER RESEARCH, 2008, 14 (08) : 2511 - 2511
  • [6] Computed tomography screening for lung cancer
    Wilck, Eric J.
    ANNALS OF THORACIC SURGERY, 2008, 85 (02): : S699 - S700
  • [7] Computed Tomography Screening for Lung Cancer
    Boiselle, Phillip M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (11): : 1163 - 1170
  • [8] Computed tomography screening for lung cancer
    Henschke, CI
    Yankelevitz, DF
    Libby, D
    McCauley, D
    Pasmantier, M
    Smith, JP
    CLINICS IN CHEST MEDICINE, 2002, 23 (01) : 49 - +
  • [9] Computed Tomography Screening for Lung Cancer
    Schmid, Eric J.
    Sundaram, Baskaran
    Kazerooni, Ella A.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2012, 50 (05) : 877 - +
  • [10] Computed Tomography Screening for Lung Cancer
    Trovato, Guglielmo M.
    Sperandeo, Marco
    Catalano, Daniela
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (02) : 155 - 155